• Oragenics signed non-binding letter of intent to license Sigyn Therapeutics’ CardioDialysis blood purification technology for traumatic brain injury, expanding its concussion and mild TBI program.
• Proposed deal grants exclusive, assignable rights to develop and commercialize CardioDialysis for TBI and other chronic neurodegenerative diseases.
• Consideration includes issuance of 3,250,000 shares of new restricted preferred stock, convertible one-for-one into common stock, subject to NYSE American rules and shareholder approval.
• Sigyn would receive 3% royalty on revenue for six years following FDA market clearance, measured from first commercial sale per indication and country.
• Target closing set for within 90 days, subject to due diligence, board approvals, independent valuation, and other customary conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oragenics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-021627), on May 07, 2026, and is solely responsible for the information contained therein.